The treatment gap: The missed opportunities for osteoporosis therapy.
Bone
; 144: 115833, 2021 03.
Article
en En
| MEDLINE
| ID: mdl-33359889
ABSTRACT
Despite substantial advances in delineation of the epidemiology, pathophysiology, risk assessment and treatment of osteoporosis over the last three decades, a substantial proportion of men and women at high risk of fracture remain untreated - the so-called "treatment gap". This review summarises the important patient-, physician- and policyrelated causes of this treatment gap, before discussing in greater detail (a) the evidence base for the efficacy of bisphosphonates in osteoporosis; (b) recent evidence relating to the adverse effects of this widely used therapeutic class, most notably atypical femoral fracture and osteonecrosis of the jaw; (c) available strategies to improve both secondary and primary prevention pathways for the management of this disorder.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Osteonecrosis
/
Osteoporosis
/
Fracturas Óseas
/
Conservadores de la Densidad Ósea
Tipo de estudio:
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Bone
Asunto de la revista:
METABOLISMO
/
ORTOPEDIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Reino Unido